# **Sarcopenia definitions as predictors of fracture risk independent of FRAX, falls and BMD in the Osteoporotic Fractures in Men (MrOS) Study: A meta-analysis**

Nicholas C Harvey1,2,Eric Orwoll3, Timothy Kwok4, Magnus K Karlsson5, Björn E Rosengren5, Eva Ribom6, Jane A Cauley7, Peggy M. Cawthon8,9, Kristine Ensrud10, Enwu Liu11, Alfonso J Cruz-Jentoft12, Roger A. Fielding13, Cyrus Cooper1,2,14, John A Kanis11,15, Mattias Lorentzon11,16, Claes Ohlsson17,19, Dan Mellström17, Helena Johansson11,15+, Eugene McCloskey15,18+

+HJ and EM are joint senior author

1MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK

2NIHR Southampton Biomedical Research Centre, University of Southampton and University Hospital Southampton NHS Foundation Trust, Tremona Road, Southampton, UK

3Oregon Health & Science University, Portland, OR, USA

4Department of Medicine & Therapeutics and School of Public Health, The Chinese University of Hong Kong, HK

5Clinical and Molecular Osteoporosis Research Unit, Department of Clinical Sciences Malmo, Lund University and Department of Orthopedics, Skane University Hospital, Malmo, Sweden

6Department of Surgical Sciences, University of Uppsala, Uppsala, Sweden

7Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh PA USA

8Research Institute, California Pacific Medical Center, San Francisco, CA USA

9Department of Epidemiology and Biostatistics, University of California, San Francisco, CA USA

10Medicine and Epidemiology & Community Health, University of Minnesota, MN, US

11Mary MacKillop Institute for Health Research, Australian Catholic University, Melbourne, Australia

12Servicio de Geriatría, Hospital Universitario Ramón y Cajal (IRYCIS), Madrid, Spain

13Nutrition, Exercise Physiology, and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center on Aging at Tufts University, Boston, MA, USA

14NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK

15Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, UK

16Geriatric Medicine, Institute of Medicine, Sahlgrenska Academy, Sahlgrenska University Hospital, Mölndal, Sweden

17Department of Internal Medicine and Clinical Nutrition, Center for Bone and Arthritis Research, Institute of Medicine, the Sahlgrenska Academy at University of Gothenburg

18Centre for Integrated research in Musculoskeletal Ageing (CIMA), Mellanby Centre for Bone Research, University of Sheffield, Sheffield, UK

19Region Västra Götaland, Sahlgrenska University Hospital, Department of Drug Treatment, Gothenburg, Sweden

+HJ and EM are joint senior author

Corresponding author:

Professor Nicholas Harvey

MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton SO16 6YD, UK

Tel: +44 23 8077 7624; Fax: +44 23 8070 4021; Email: [nch@mrc.soton.ac.uk](mailto:nch@mrc.soton.ac.uk)

Running title: Sarcopenia, FRAX and fractures

Word count:

Tables: 4

Figures: 1

**Abstract**

DXA-appendicular lean mass/height2 (ALM/ht2) is the most commonly used estimate of muscle mass in the assessment of sarcopenia, but its predictive value for fracture is substantially attenuated by femoral neck(fn) bone mineral density(BMD). We investigated predictive value of 11 sarcopenia definitions for incident fracture, independent of fnBMD, FRAX® probability and prior falls, using an extension of Poisson regression in US, Sweden and Hong Kong MrOS cohorts. Definitions tested were those of Baumgartner and Delmonico (ALM/ht2 only), Morley, the International Working Group on Sarcopenia, European Working Group on Sarcopenia in Older People(EWGSOP1 & 2), Asian Working Group on Sarcopenia, Foundation for the National Institutes of Health 1 & 2 (using ALM/BMI), (incorporating muscle strength and/or physical performance measures plus ALM/ht2), and Sarcopenia Definitions and Outcomes Consortium (gait speed and grip strength). Associations were adjusted for age and time since baseline and reported as hazard ratio (HR) for first incident fracture, here major osteoporotic fracture (MOF: clinical vertebral, hip, distal forearm, proximal humerus). Further analyses adjusted additionally for FRAX-MOF probability (n=7531; calculated+/-fnBMD), prior falls(y/n) or fnBMD T-score. Results were synthesized by meta-analysis. In 5660 men in USA, 2764 Sweden and 1987 Hong Kong (mean ages 73.5, 75.4 and 72.4 years respectively; sarcopenia prevalence ranged from 0.5% to 35%. Sarcopenia status, by all definitions except those of FNIH, was associated with incident MOF (HR: 1.39 to 2.07). Associations were robust to adjustment for prior falls or FRAX probability (without fnBMD); adjustment for fnBMD T-score attenuated associations. EWGSOP2 severe sarcopenia (incorporating chair stand-time, gait speed and grip strength plus ALM) was most predictive, albeit at low prevalence, and appeared only modestly influenced by inclusion of fnBMD. In conclusion, the predictive value for fracture of sarcopenia definitions based on ALM is reduced by adjustment for fnBMD, but strengthened by additional inclusion of physical performance measures.

**Key words:** Osteoporosis; epidemiology; FRAX; sarcopenia; falls; fracture; interaction

**Funding**

The Osteoporotic Fractures in Men (MrOS) Study is supported by National Institutes of Health funding. The following institutes provide support: The National Institute on Aging (NIA), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Center for Advancing Translational Sciences (NCATS), and NIH Roadmap for Medical Research under the following grant numbers: U01 AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168, U01 AR066160, and UL1 TR000128. MrOS Sweden is supported by the Swedish Research Council, ALF/LUA research grants in Gothenburg, and the King Gustav V and Queen Victoria Frimurarestiftelse Research Foundation. Dr. Fielding is supported by the U.S. Department of Agriculture (USDA), under agreement No. 58-1950-4-003. Any opinions, findings, conclusions, or recommendations expressed in this publication are those of the authors and do not necessarily reflect the view of the USDA. The work was also supported by the UK Medical Research Council (4050502589 (MRC LEU)).

**Introduction**

Sarcopenia, (accelerated loss of muscle strength, function and mass),(1) while now having an associated ICD code, presents a diagnostic challenge, given the current wide range of approaches to its operational definition. By various definitions sarcopenia has been associated with outcomes such as falls, fractures and death,(1) but it is increasingly apparent that there are limitations inherent in these approaches resulting from DXA derived appendicular lean mass (ALM) being a component part.(2,3) We have recently demonstrated that the predictive capacity of DXA ALM for incident fracture, in the three Osteoporotic Fractures in Men (MrOS) cohorts, is attenuated to the null by inclusion of femoral neck BMD T-score.(4) Similar findings have been observed in the US Health ABC(5) and WHI cohorts(6) and are recognized in recent recommendations from the Sarcopenia Definitions and Outcomes Consortium (SDOC).(7,8) Other than that from SDOC, current definitions of sarcopenia incorporate DXA ALM as the measure of muscle mass, either alone, or in the newer definitions, together with measures of physical function/performance/strength, such as gait speed and grip strength. Indeed the most recent European Working Group algorithm moves the focus from ALM to that of performance/function and strength as the important attributes.(9) Given the centrality of DXA ALM to current sarcopenia definitions, and the apparent weakness of ALM as a predictor of incident fracture after adjustment for bone mineral density (BMD), an important unanswered question is whether the predictive capacity for fracture of these sarcopenia definitions remains when bone mineral density is also taken into account. Clinically, there would seem little point in undertaking the assessments required for sarcopenia definition (including whole body DXA, gait speed and grip strength for example) if the risk information conveyed by the assessment tells us nothing beyond that associated with femoral neck BMD (a very quick measure to obtain). This consideration also applies to independence from FRAX probability and prior history of falls. A further unanswered question therefore relates to the magnitude of the risk relationships between sarcopenia definitions and fracture outcomes with these various adjustments. Finally, it unknown how these associations might vary by age, an important consideration in terms of clinical impact. We therefore undertook a meta-analysis of the three Osteoporotic Fractures in Men (MrOS) cohorts (US, Sweden, Hong Kong) to investigate whether the predictive value of sarcopenia definitions for incident fracture was independent of BMD, FRAX probability and history of falls; and to quantify the magnitude and age dependence of these associations.

**Methods**

*Participants*

Details of the Osteoporotic Fractures in Men (MrOS) cohort studies have been published previously,(4,10-13) but briefly, MrOS is a multicentre study of community-dwelling men age 65 years or older from three international cohorts, recruited and evaluated using similar protocols. To be eligible for the study, subjects had to be able to walk without aid. In the MrOS Hong Kong Study, 2,000 Chinese men, age 65–92 years, were enrolled between August 2001 and February 2003.(14) All were Hong Kong residents of Asian ethnicity. Stratified sampling was adopted to ensure that 33% of subjects were included in each of the following age groups: 65–69, 70–74 and ≥75 years. Recruitment notices were placed in housing estates and community centres for the elderly. In the MrOS Sweden Study, 3014 men, age 69–81 years, were enrolled between October 2001 and December 2004.(12,15) The cohort comprised men from the cities of Malmo, Gothenburg and Uppsala, identified and recruited using national population registers. More than 99% were of Caucasian ethnicity. The participation rate in the MrOs Sweden Study was 45%. In the MrOS United States Study, 5994 men, aged 65–100 years, were enrolled at 6 sites between March 2000 and April 2002.(16,17) Each US clinical site designed and customised strategies to enhance recruitment of its population. Common strategies included mailings from the Department of Motor Vehicles, voter registration and participant databases, common senior newspaper features and advertisement and targeted presentations. Self-defined racial/ethnic ancestry was ascertained through questionnaires at baseline (90% White ethnicity).

*Exposure variables*

The international MrOS questionnaire(16) was administered at baseline to collect information about current smoking, number and type of medications, fracture history, family history of hip fracture, past medical history (rheumatoid arthritis) and high consumption of alcohol (3 or more glasses of alcohol-containing drinks per day), calculated from the reported frequency and amount of alcohol use. Previous fracture at baseline was documented as all fractures after the age of 50 years, regardless of trauma. For glucocorticoid exposure, this was documented in MrOS as use at least 3 times per week in the month preceding the baseline assessment. Apart from glucocorticoid use and rheumatoid arthritis (both FRAX input variables), there was no information on secondary causes of osteoporosis and the “Secondary Osteoporosis” input variable for FRAX probability calculation was set to no for all men. Self-reported falls during the 12 months preceding the baseline were recorded by questionnaire (past falls).

At baseline, height (centimeters) and weight (kilograms) were measured, and BMI was calculated as kilograms per square meter. Time to complete 5 chair stands, walking speed over 6m (at usual pace) and grip strength using JAMAR dynamometers (Sammons Preston Rolyan, Bolingbrook, IL, US) were assessed at the baseline visit. Areal bone mineral density (BMD) was measured at the femoral neck, and appendicular lean mass from whole body scans, using Hologic QDR 4500 A or W (Hologic, Bedford, MA) or Lunar Prodigy (GE Lunar Corp., Madison, WI) depending on the centre, with cross calibration of instruments for BMD. A T-score was calculated using NHANES young women (Caucasian) as a reference value.(18,19) In the subset in which the necessary variables were available (n=7531), FRAX 10-year probability of major osteoporotic fracture (MOF; hip, humerus, vertebral or forearm sites) was calculated using clinical risk factors described above with and without femoral neck BMD entered into country-specific FRAX models.

*Fracture and death outcomes*

*Hong Kong:(20)* Incident fractures were captured via subject follow-up through phone call or visit to the research centre. All fracture sites (hip, wrist, skull/face, ribs, shoulder, arm, wrist, vertebra, tibia, fibula, foot, metatarsal toes, hand, fingers, and pelvis) were recorded. Pathological fractures were excluded. Only incident fractures reported by participants and confirmed by X-ray or medical record review were included. Deaths were verified by death certificates.

*Sweden:(21)* Central registers covering all Swedish citizens were used to identify the subjects and the date of death for all subjects who died during the study. For incident fracture evaluation, the computerized X-ray archives in Malmo, Gothenborg, and Uppsala were searched for new fractures occurring after the baseline visit using the unique personal registration number allocated to every Swedish citizen. If additional fractures were reported by the study subject after the baseline visit, these were only included if confirmed by physician review of radiology reports.

*US:(16)* Triannual questionnaires were mailed to each participant. If a participant reported a fracture, study staff conducted a follow-up telephone interview to determine the date the fracture had occurred, a description of how the fracture occurred, the type of trauma that resulted in the fracture, the participant’s location and activities at the time of the fracture, symptoms just before or coincident with the fracture, and source of medical care for the fracture. All reported fractures were centrally verified by a physician adjudicator through medical records. Deaths were verified through centralized review of state death certificates.

*Sarcopenia definitions*

Individuals were classified as sarcopenic or non-sarcopenic according to each individual sarcopenia definition, as published by International Working group on Sarcopenia (IWGS)(22), Baumgartner(23), European Working Group on Sarcopenia in Older People (EWGSOP1)(24), Morley(25), Delmonico(26,27), Asian Working Group on Sarcopenia (AWGS)(28) and the Foundation for the National Institutes of Health (FNIH 1&2)(29), together with the recently published revised EWGSOP2 guidelines, incorporating definitions of “confirmed” and “severe sarcopenia”,(9) and the recent US guidelines from the Sarcopenia Definitions and Outcomes Consortium (SDOC).(7,8) Thus 11 sarcopenia definitions were explored as the exposure. The majority of these guidelines use thresholds derived from expert consensus, and all include a measure of appendicular lean mass. In all but the two data driven FNIH definitions (in which appendicular lean mass is divided by body mass index) this was incorporated as appendicular lean mass divided by height squared. In the earlier definitions [Baumgartner, Delmonico, FNIH1] the presence of sarcopenia is based solely on the measure of appendicular lean mass. In later definitions [FNIH2, IWGS, EWGSOP 1 and 2, Morley and AWGS] this is combined with the requirement for impaired strength or function, assessed through grip strength, chair stand time or gait speed. In EWGSOP2 “confirmed” sarcopenia was based on low DXA ALM/height2 in combination with increased chair stand time or low grip strength; additional low gait speed constituted severe sarcopenia. The SDOC approach dispenses with ALM entirely. The cut points used in the sarcopenia definitions, together with the prevalence of each definition by cohort, are demonstrated in Table 1.

*Statistical methods*

Clinical outcomes comprised: any fracture, osteoporotic fracture (defined according to Kanis et al. 2001(30) as clinical vertebral, ribs, pelvis, humerus, clavicle, scapula, sternum, hip, other femoral fractures, tibia, fibula, distal forearm/wrist), MOF and hip fracture. An extension of Poisson regression models(31) was used to study the association between the future risk of fracture and sarcopenia, FRAX, prior falls, and BMD. All associations were adjusted for age and time since baseline. In contrast to logistic regression, the Poisson regression uses the length of each individual’s follow-up period and the hazard function is assumed to be exp(β0 + β1 · current time from baseline + β2 · current age + β3 · variable of interest). The observation period of each participant was divided into intervals of one month. One fracture per person, and time to the first fracture, were counted, and time at risk was censored at the time of first fracture, loss to follow-up, death or end of follow up. Unlike a Cox model, the Poisson model uses a data duplication method, accounting for the competing mortality risk for fracture risk prediction.(32) We initially investigated the predictive value of each sarcopenia definition adjusted only for age and follow-up time. Subsequently, we used multivariate models to investigate the predictive value of these definitions independent of FRAX, prior falls or BMD (entered into the model as femoral neck T-score). The association between sarcopenia definition (yes/no) and risk of fracture is presented as a hazard ratio (HR) together with 95% confidence intervals (CI). Two-sided p-values were used for all analyses and p<0.05 considered to be significant. Analyses were undertaken separately within each cohort and then the β-coefficients from each cohort were weighted according to the variance, and merged to determine the weighted mean of the coefficient and its standard deviation (fixed-effects meta-analysis, since heterogeneity was low to moderate as assessed by I2).(33) The risk ratios are then given by e(weighted mean coefficient). Finally, we investigated whether the magnitude of associations differed by age.

**Results**

*Characteristics of participants*

The study cohort consisted of 10,411 men who had information on the key exposures, together with prior falls and femoral neck BMD:(4) 5660 men in USA (mean age 73.5 years; mean follow-up 10.9 years); 2764 men in Sweden (mean age 75.4 years; mean follow-up 8.7 years); and 1987 men in Hong Kong (mean age 72.4 years; mean follow-up 9.9 years), Table 2. Previous fracture was more commonly reported in Sweden (35%) than in the USA (22%) and Hong Kong (14%). The frequency of past falls was similar across the cohorts at 20%, 16%, and 15% respectively. Consistent with the known country-specific epidemiology of fracture, the highest mean FRAX MOF probability (with BMD) was observed in Sweden (11.4%), followed by USA (7.8%) and Hong Kong (6.6%). Online Supplementary Table 1 presents the baseline characteristics according to whether FRAX probability was available for analysis or not, demonstrating that overall, the populations with or without FRAX were similar within countries.

*Proportion of cohort defined as sarcopenic by individual definition*

The proportion of the population defined as sarcopenic varied markedly by individual definition, much more so than by country cohort, Table 1. Thus, the Baumgartner definition gave the highest prevalence in all 3 cohorts (35% in Hong Kong; 22% in Sweden and 21% in US). In contrast the proportion who were defined as sarcopenic was tenfold or more lower using the FNIH2 definition (4% in Hong Kong; 0.4% in Sweden and 0.9% in US). The EWGSOP2 severe sarcopenia definition also yielded low prevalences; 3.6% Hong Kong, 0.6% Sweden, 0.5% USA.

*Associations between sarcopenia definition and incident fracture*

In base models adjusted for age and follow-up time only, all sarcopenia definitions other than FNIH 1 and 2 were predictive of incident fracture across the fracture groupings. Overall, the Baumgartner and Delmonico definitions, which are based on ALM alone, had somewhat lower hazard ratios for fracture (Baumgartner HR for MOF (95%CI): 1.39 (1.22, 1.58) and Delmonico, HR for MOF (95%CI): 1.40 (1.23, 1.59)] than did the definitions incorporating ALM and a measure of function or strength, from IWGS, EWGSOP (1 and 2-confirmed), Morley and AWGS, with hazard ratios for MOF ranging from 1.60 to 1.92. The highest hazard ratios were for the SDOC and EWGSOP2 severe sarcopenia definitions: for example, EWGSOP2 severe, MOF: HR=2.07 (95%CI: 1.28, 3.33) and hip: HR=2.40 (95%CI: 1.26, 4.57), albeit with relatively wide confidence intervals. These associations are summarised in Table 3 and Figure 1, and representative associations by country cohort are presented in Online Supplementary Table 2.

*Effect of adjustment for prior falls, FRAX probability or femoral neck BMD T-score*

Table 3 and Figure 1 demonstrate that inclusion of prior falls or FRAX MOF probability (calculated without or with femoral neck BMD) in the models in addition to age and follow-up time did not materially change the magnitude of the relationships. In contrast, inclusion of femoral neck BMD T-score in addition to age and follow-up time attenuated the predictive value of sarcopenia definitions. Indeed, the definitions of Baumgartner and Delmonico, together with that of Morley, were no longer statistically significant predictors of incident major osteoporotic fracture. The predictive capacity of the SDOC and EWGSOP2 severe definition appeared rather less attenuated after adjustment for BMD, such that, e.g. for EWGSOP2 severe, the hazard ratio (95%CI) for MOF was 1.80 (1.12, 2.19) and for hip fracture was 2.31 (1.21, 4.41).

*Interaction between predictive value and age*

We investigated whether the magnitude of association between sarcopenia presence and incident fracture differed by age. There was evidence of such an effect, summarised in Table 4 for EWGSOP2 confirmed definition as a representative example. Thus the HR ranged from 3.24 (95%CI: 1.88, 5.58) for major osteoporotic fracture at age 70 years to 1.73 (95%CI: 1.35, 2.23) at 85 years, p-interaction=0.023. Results for EWGSOP2 confirmed together with other representative definitions are presented in Online Supplementary Table 3.

**Discussion**

In this large population of older men, uniformly assessed across three international cohorts, we observed that sarcopenia definitions other than those based on ALM divided by BMI were modestly predictive of incident fractures, but that this association was attenuated when femoral neck BMD T-score was incorporated in the regression models. The SDOC and EWGSOP2 severe sarcopenia definitions appeared the most predictive of fracture outcomes, but at low population prevalences. Indeed, as has been observed elsewhere,(34) the prevalence of sarcopenia varied tenfold or more according to individual definitions within each country cohort, which clearly presents some practical difficulties with the operationalization of sarcopenia definitions in clinical practice, or in their use as endpoints in clinical trials of agents aimed at treating sarcopenia. This variability will also have an obvious impact on global sarcopenia epidemiology.

Our recent findings that ALM/height2, a key component of sarcopenia definitions, is poorly predictive of incident fractures in men and women (and even potentially a risk factor for hip fractures) after adjustment for femoral neck BMD(4,35) are consistent with previous studies in the Women’s Health Initiative (WHI). In one analysis, WHI participants were classified into mutually exclusive groups based on BMD and sarcopenia (dichotomous variable according to appendicular lean mass adjusted for height and fat mass) status.(6) Whilst low BMD was associated with increased risk of hip fracture, women with sarcopenia alone had similar hazard ratios of hip fracture to non-sarcopenic women with normal BMD, suggesting that sarcopenia alone is not predictive of hip fracture. In a further WHI study appendicular lean mass was predictive of incident hip fracture amongst 872 participants 65 years or older who met Fried’s criteria for frailty, but this association did not remain statistically significant after adjusting for total hip BMD.(36)

Sarcopenia definitions of course reflect the contribution of their constituent parts, be that appendicular lean mass alone or together with gait speed and physical performance measures or grip strength.(2) Evidence to date suggests that it is the appendicular lean mass component, derived from DXA, which limits the predictive capacity of sarcopenia definitions for incident fracture, particularly when femoral neck BMD T-score is also included.(2) Thus, we demonstrated in MrOS that DXA ALM is modestly predictive of incident fracture independently of past falls and FRAX probability.(4) However the relationship was markedly attenuated by the addition of femoral neck BMD T-score, and indeed greater ALM (or ALM/ht2) appeared to be a risk factor for hip fracture after accounting for femoral neck BMD. A similar finding was observed in the Health ABC study,(5) with the findings possibly suggesting that muscle mass in excess of bone mass might be a pro-fracture state. However, this would seem to be at odds with the general adaptation of bone to muscle,(37) and excess muscle mass or power over bone strength seems unlikely in older men (compared with younger athletes for example). Similar findings come from the Framingham study,(38) although in the Swiss GERICO study, adjustment of low lean mass for BMD did not substantially attenuate associations with incident fracture(39), and differential patterns by sex have been noted elsewhere.(7)

The reason for this limited value of DXA appendicular lean mass in the prediction of fracture, and indeed in the prediction of other outcomes such as falls and mortality, may reflect several potential factors.(2) Firstly, ALM is not a direct measure of muscle itself, but reflects all of the non-fat, non-bone tissue within the body.(40) Secondly it is derived from the same measurement instrument as femoral neck BMD; the body composition equations incorporate two compartments to solve the third meaning that a mathematical relationship between lean mass and BMD is inevitable.(40) Thirdly, there is a clear biological relationship between lean mass muscle and bone, elegantly laid out in the mechanostat hypothesis.(37) Thus there is the potential for ALM to act as a surrogate for BMD if this relationship is not considered. Indeed, in our recent analysis of the MrOS cohort, measures of physical performance such as gait speed and chair stand time, together with grip strength, appeared to be rather more robust predictors of incident fracture than did DXA ALM, (4) supporting the notion that it is the non-DXA components of the more recent sarcopenia definitions which drive relationships with incident fracture. Other studies have similarly demonstrated the greater predictive capacity of physical function over DXA ALM as an estimate of muscle mass. (41-45)

Taken together, these findings suggest that alternative measures of muscle, such as creatine dilution,(46) or muscle cross sectional area or density from (p)QCT,(47-49) may offer a more useful measure on which to base sarcopenia definitions. These notions have been recognised in the recently revised guidelines from the US Sarcopenia Definitions and Outcomes Consortium, which dispenses with ALM completely, and from the European Working Group on Sarcopenia in Older People (EWGSOP2), which incorporates muscle strength rather than mass as the initial assessment, with the latter assessable via a range of measures rather than simply DXA ALM(50). Of note is that the resulting SDOC and EWGSOP2 severe sarcopenia definitions within this revised guidance were associated with the greatest magnitude of association with incident fracture outcomes in our analyses, and that these associations were only modestly attenuated by incorporation of femoral neck BMD T-score. The EWGSOP2 cut-offs for ALM/height2, gait speed and grip strength were similar to those used in the AWGS definition (which is of course predicated on the generally smaller body size in the Asian population), and for grip strength, in the FNIH2 definition, but differs in the incorporation of chair stand time (previously shown to predict fracture risk(4,44)) from AWGS and in use of ALM/ht2 rather than ALM/BMI from FNIH2. It is therefore likely that this additional functional component reduces the attenuating effect of BMD, but this apparent advantage must be taken in the context of the very low population prevalence of sarcopenia using these criteria. It is notable that adjustment for FRAX probability calculated with inclusion of femoral neck BMD had a much less obvious influence on these associations. Whilst this may at first sight appear surprising, it is important to recognise that femoral neck BMD T-score is a very different construct to FRAX probability calculated with BMD as one of several input variables, all interlinked through a multivariate structure and generating a probability over 10 years which synthesizes risk of fracture with risk of death.

The evidence of an age interaction (illustrated for the EWGSOP2 definition in Table 5, and for all definitions in the Online Supplementary Table 1) suggests that sarcopenia is actually more predictive of fracture at younger compared with older ages, although given the potential for healthy selection bias in cohorts, it is possible that a less marked pattern would be observed in a completely unselected general population. Importantly the Poisson model uses a data duplication approach which accounts for the competing hazard of mortality, thus reducing the likelihood that this finding is simply due to higher mortality at older ages. Whilst this may lessen the clinical impact of such definitions in the populations at highest risk, this observation is similar to the age patterns documented with many risk factors; essentially, occurrence of a risk factor becomes less unusual compared with general population as age increases. The perhaps more pertinent clinical implication arises in the markedly diverse range of prevalences according to definition and country cohort. Clearly a definition which detects less than 0.5% of the population as having the condition of interest is likely to have very limited impact on healthcare, a notion which seems rather at odds with the widespread recognition of the increasingly elderly and frail populations in many countries globally.(51)

We studied three well-characterized cohorts drawn from general populations with standardized assessments and prospective recording of fractures. However, there are some limitations that should be considered in the interpretation of our findings.(16) Firstly, the population studied was exclusively male, and of a modest age range (64-99 years), so limiting generalizability of our findings. Secondly, we were limited to DXA measures of lean mass, so that both lean and bone measures were obtained from the same scanner and DXA only approximates muscle mass. Thirdly, comparison of predictive value would ideally compare exposures with similar prevalence in the population. Since the sarcopenia definitions were dichotomous, this was clearly not feasible, and it is therefore possible that some of the difference in the effect size between definitions was determined by the differences in prevalence. Indeed it is notable however that patterns for the EWGSOP2 confirmed, Morley and AWGS, which were all of similar prevalence, were broadly similar. Fourthly, there was no information on causes of secondary osteoporosis (other than rheumatoid arthritis and glucocorticoids), and this variable was therefore set to null. The effect of these considerations on our findings is uncertain, but may have led to an underestimation of risk by FRAX. Finally, the definition of glucocorticoid use differed from those usually specified for incorporation into FRAX.

In conclusion, we have demonstrated novel findings that sarcopenia definitions based on appendicular lean mass corrected for height squared, but not corrected for BMI, are modestly predictive of incident fracture after adjustment for FRAX probability, and more so for those definitions also incorporating measures of physical performance and/or muscle strength. The predictive value of such definitions may vary with age and is attenuated to different degrees by the inclusion of femoral neck BMD T-score. This latter observation is consistent with numerous observations suggesting the limited value of DXA appendicular lean mass as a measure of muscle in fracture risk assessment, but has not been quantified previously. Our findings thus support the inclusion of physical performance measures in the assessment of sarcopenia, and also the investigation of alternative measures of muscle such as creatine dilution and pQCT, which may prove to be more usefully incorporated into sarcopenia definitions, at least in the context of predicting incident fractures.

**Acknowledgments**

We thank the participants of MrOs US, Sweden and Hong Kong. The Osteoporotic Fractures in Men (MrOS) Study is supported by National Institutes of Health funding. The following institutes provide support: the National Institute on Aging (NIA), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Center for Advancing Translational Sciences (NCATS), and NIH Roadmap for Medical Research under the following grant numbers: U01 AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168, U01 AR066160, and UL1 TR000128. MrOS Sweden is supported by the Swedish Research Council, ALF/LUA research grants in Gothenburg, and the King Gustav V and Queen Victoria Frimurarestiftelse Research Foundation. The work was also supported by the UK Medical Research Council (4050502589 (MRC LEU)).

**Author Roles**

All authors contributed to manuscript drafting, review and finalisation. NCH wrote the first draft of the manuscript and oversaw its preparation; HJ and EL undertook statistical analysis; EO, JL, JC, PC, KE designed and implemented MrOS US, and provided data; MK, BR, ER, CO, DM designed and implemented MrOS Sweden, and provided data; TK designed and implemented MrOS Hong Kong, and provided data; CC and ML contributed expertise on fracture epidemiology; ACJ and RAF contributed expertise on sarcopenia definitions and derivation; EVM and JAK oversee FRAX and provided FRAX methodology; NCH is guarantor.

**Disclosures**

All authors have no disclosures in relation to this manuscript.

References

1. Cruz-Jentoft AJ, Sayer AA. Sarcopenia. Lancet. Jun 29 2019;393(10191):2636-46. Epub 2019/06/07.

2. Harvey NC, Kanis JA, Liu E, Johansson H, Lorentzon M, McCloskey E. Appendicular lean mass and fracture risk assessment: implications for FRAX(R) and sarcopenia. Osteoporos Int. Mar 2019;30(3):537-9. Epub 2019/03/01.

3. Buckinx F, Landi F, Cesari M, Fielding RA, Visser M, Engelke K, et al. Pitfalls in the measurement of muscle mass: a need for a reference standard. Journal of cachexia, sarcopenia and muscle. Apr 2018;9(2):269-78. Epub 2018/01/20.

4. Harvey NC, Oden A, Orwoll E, Lapidus J, Kwok T, Karlsson MK, et al. Measures of Physical Performance and Muscle Strength as Predictors of Fracture Risk Independent of FRAX, Falls, and aBMD: A Meta-Analysis of the Osteoporotic Fractures in Men (MrOS) Study. J Bone Miner Res. Dec 2018;33(12):2150-7. Epub 2018/07/17.

5. Malkov S, Cawthon PM, Peters KW, Cauley JA, Murphy RA, Visser M, et al. Hip fractures risk in older men and women associated with DXA-derived measures of thigh subcutaneous fat thickness, cross-sectional muscle area, and muscle density. J Bone Miner Res. Aug 2015;30(8):1414-21. Epub 2015/02/04.

6. Harris R, Chang Y, Beavers K, Laddu-Patel D, Bea J, Johnson K, et al. Risk of Fracture in Women with Sarcopenia, Low Bone Mass, or Both. J Am Geriatr Soc. Sep 27 2017. Epub 2017/09/30.

7. Bhasin S, Travison TG, Manini TM, Patel S, Pencina KM, Fielding RA, et al. Sarcopenia Definition: The Position Statements of the Sarcopenia Definition and Outcomes Consortium. J Am Geriatr Soc. Mar 9 2020. Epub 2020/03/10.

8. Cawthon PM, Manini T, Patel SM, Newman A, Travison T, Kiel DP, et al. Putative Cut-Points in Sarcopenia Components and Incident Adverse Health Outcomes: An SDOC Analysis. J Am Geriatr Soc. Jul 2020;68(7):1429-37. Epub 2020/07/08.

9. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. Jan 1 2019;48(1):16-31. Epub 2018/10/13.

10. Karlsson MK, Ribom E, Nilsson JA, Ljunggren O, Ohlsson C, Mellstrom D, et al. Inferior physical performance tests in 10,998 men in the MrOS study is associated with recurrent falls. Age Ageing. Nov 2012;41(6):740-6. Epub 2012/08/28.

11. Rosengren BE, Ribom EL, Nilsson JA, Mallmin H, Ljunggren O, Ohlsson C, et al. Inferior physical performance test results of 10,998 men in the MrOS Study is associated with high fracture risk. Age Ageing. May 2012;41(3):339-44. Epub 2012/02/09.

12. Harvey NC, Johansson H, Oden A, Karlsson MK, Rosengren BE, Ljunggren O, et al. FRAX predicts incident falls in elderly men: findings from MrOs Sweden. Osteoporos Int. Jan 2016;27(1):267-74. Epub 2015/09/24.

13. Harvey NC, Oden A, Orwoll E, Lapidus J, Kwok T, Karlsson M, et al. Falls predict fractures independently of FRAX probability: A meta-analysis of the Osteoporotic Fractures in Men (MrOS) Study. J Bone Miner Res. 2017;In press.

14. Lau EM, Leung PC, Kwok T, Woo J, Lynn H, Orwoll E, et al. The determinants of bone mineral density in Chinese men--results from Mr. Os (Hong Kong), the first cohort study on osteoporosis in Asian men. OsteoporosInt. 2006;17(2):297-303.

15. Mellstrom D, Johnell O, Ljunggren O, Eriksson AL, Lorentzon M, Mallmin H, et al. Free testosterone is an independent predictor of BMD and prevalent fractures in elderly men: MrOS Sweden. J Bone Miner Res. Apr 2006;21(4):529-35. Epub 2006/04/07.

16. Orwoll E, Blank JB, Barrett-Connor E, Cauley J, Cummings S, Ensrud K, et al. Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study--a large observational study of the determinants of fracture in older men. Contemp Clin Trials. Oct 2005;26(5):569-85. Epub 2005/08/09.

17. Blank JB, Cawthon PM, Carrion-Petersen ML, Harper L, Johnson JP, Mitson E, et al. Overview of recruitment for the osteoporotic fractures in men study (MrOS). Contemporary clinical trials. Oct 2005;26(5):557-68. Epub 2005/08/09.

18. Looker AC, Wahner HW, Dunn WL, Calvo MS, Harris TB, Heyse SP, et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int. 1998;8(5):468-89. Epub 1998/12/16.

19. Kanis JA, Adachi JD, Cooper C, Clark P, Cummings SR, Diaz-Curiel M, et al. Standardising the descriptive epidemiology of osteoporosis: recommendations from the Epidemiology and Quality of Life Working Group of IOF. Osteoporos Int. Nov 2013;24(11):2763-4. Epub 2013/07/26.

20. Kwok T, Khoo CC, Leung J, Kwok A, Qin L, Woo J, et al. Predictive values of calcaneal quantitative ultrasound and dual energy X ray absorptiometry for non-vertebral fracture in older men: results from the MrOS study (Hong Kong). Osteoporos Int. Mar 2012;23(3):1001-6. Epub 2011/04/30.

21. Ohlsson C, Mellstrom D, Carlzon D, Orwoll E, Ljunggren O, Karlsson MK, et al. Older men with low serum IGF-1 have an increased risk of incident fractures: the MrOS Sweden study. J Bone Miner Res. Apr 2011;26(4):865-72. Epub 2011/03/25.

22. Fielding RA, Vellas B, Evans WJ, Bhasin S, Morley JE, Newman AB, et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia. J Am Med Dir Assoc. May 2011;12(4):249-56. Epub 2011/04/30.

23. Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. Apr 15 1998;147(8):755-63. Epub 1998/04/29.

24. Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. Jul 2010;39(4):412-23. Epub 2010/04/16.

25. Morley JE, Abbatecola AM, Argiles JM, Baracos V, Bauer J, Bhasin S, et al. Sarcopenia with limited mobility: an international consensus. J Am Med Dir Assoc. Jul 2011;12(6):403-9. Epub 2011/06/07.

26. Delmonico MJ, Harris TB, Lee JS, Visser M, Nevitt M, Kritchevsky SB, et al. Alternative definitions of sarcopenia, lower extremity performance, and functional impairment with aging in older men and women. J Am Geriatr Soc. May 2007;55(5):769-74. Epub 2007/05/12.

27. Delmonico MJ, Harris TB, Visser M, Park SW, Conroy MB, Velasquez-Mieyer P, et al. Longitudinal study of muscle strength, quality, and adipose tissue infiltration. Am J Clin Nutr. Dec 2009;90(6):1579-85.

28. Chen LK, Lee WJ, Peng LN, Liu LK, Arai H, Akishita M. Recent Advances in Sarcopenia Research in Asia: 2016 Update From the Asian Working Group for Sarcopenia. J Am Med Dir Assoc. Aug 1 2016;17(8):767 e1-7. Epub 2016/07/04.

29. Studenski SA, Peters KW, Alley DE, Cawthon PM, McLean RR, Harris TB, et al. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. J Gerontol A Biol Sci Med Sci. May 2014;69(5):547-58.

30. Kanis JA, Oden A, Johnell O, Jonsson B, de Laet C, Dawson A. The burden of osteoporotic fractures: a method for setting intervention thresholds. Osteoporos Int. 2001;12(5):417-27. Epub 2001/07/11.

31. Breslow NE, Day NE. Statistical Methods in Cancer Research. IARC Scientific Publications No 32. 1987;Volume II:p 131-5.

32. Lunn M, McNeil D. Applying Cox regression to competing risks. Biometrics. Jun 1995;51(2):524-32. Epub 1995/06/01.

33. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Bmj. Sep 06 2003;327(7414):557-60. Epub 2003/09/06.

34. Bischoff-Ferrari HA, Orav JE, Kanis JA, Rizzoli R, Schlogl M, Staehelin HB, et al. Comparative performance of current definitions of sarcopenia against the prospective incidence of falls among community-dwelling seniors age 65 and older. Osteoporos Int. Dec 2015;26(12):2793-802. Epub 2015/06/13.

35. Harvey NC, Kanis JA, Liu E, Cooper C, Lorentzon M, Bea JW, et al. Predictive Value of DXA Appendicular Lean Mass for Incident Fractures, Falls, and Mortality, Independent of Prior Falls, FRAX, and BMD: Findings from the Women's Health Initiative (WHI). J Bone Miner Res. Jan 15 2021. Epub 2021/01/16.

36. Zaslavsky O, Li W, Going S, Datta M, Snetselaar L, Zelber-Sagi S. Association between body composition and hip fractures in older women with physical frailty. Geriatrics & gerontology international. Jun 2017;17(6):898-904. Epub 2016/05/11.

37. Seeman E. Structural basis of growth-related gain and age-related loss of bone strength. Rheumatology (Oxford). Jul 2008;47 Suppl 4:iv2-8. Epub 2008/07/02.

38. McLean RR, Kiel DP, Berry SD, Broe KE, Zhang X, Cupples LA, et al. Lower Lean Mass Measured by Dual-Energy X-ray Absorptiometry (DXA) is Not Associated with Increased Risk of Hip Fracture in Women: The Framingham Osteoporosis Study. Calcif Tissue Int. Jan 5 2018. Epub 2018/01/07.

39. Hars M, Biver E, Chevalley T, Herrmann F, Rizzoli R, Ferrari S, et al. Low Lean Mass Predicts Incident Fractures Independently From FRAX: a Prospective Cohort Study of Recent Retirees. J Bone Miner Res. Nov 2016;31(11):2048-56. Epub 2016/06/03.

40. Dual energy x-ray absorptiometry for bone mineral density and body composition assessment. IAEA Human Health Series No 15. Vienna: International Atomic Energy Authority; 2010.

41. Cawthon PM, Fullman RL, Marshall L, Mackey DC, Fink HA, Cauley JA, et al. Physical performance and risk of hip fractures in older men. J Bone Miner Res. Jul 2008;23(7):1037-44. Epub 2008/02/28.

42. Cauley JA, Harrison SL, Cawthon PM, Ensrud KE, Danielson ME, Orwoll E, et al. Objective measures of physical activity, fractures and falls: the osteoporotic fractures in men study. J Am Geriatr Soc. Jul 2013;61(7):1080-8. Epub 2013/07/17.

43. Ensrud KE, Blackwell TL, Cauley JA, Dam TT, Cawthon PM, Schousboe JT, et al. Objective measures of activity level and mortality in older men. J Am Geriatr Soc. Nov 2014;62(11):2079-87. Epub 2014/11/05.

44. Cawthon PM, Blackwell TL, Marshall LM, Fink HA, Kado DM, Ensrud KE, et al. Physical performance and radiographic and clinical vertebral fractures in older men. J Bone Miner Res. Sep 2014;29(9):2101-8. Epub 2014/07/22.

45. Chan BK, Marshall LM, Winters KM, Faulkner KA, Schwartz AV, Orwoll ES. Incident fall risk and physical activity and physical performance among older men: the Osteoporotic Fractures in Men Study. AmJEpidemiol. 2007;165(6):696-703.

46. Cawthon PM, Orwoll ES, Peters KE, Ensrud KE, Cauley JA, Kado DM, et al. Strong Relation Between Muscle Mass Determined by D3-creatine Dilution, Physical Performance, and Incidence of Falls and Mobility Limitations in a Prospective Cohort of Older Men. J Gerontol A Biol Sci Med Sci. May 16 2019;74(6):844-52. Epub 2018/06/14.

47. Lang T, Cauley JA, Tylavsky F, Bauer D, Cummings S, Harris TB. Computed tomographic measurements of thigh muscle cross-sectional area and attenuation coefficient predict hip fracture: the health, aging, and body composition study. J Bone Miner Res. Mar 2010;25(3):513-9. Epub 2010/04/28.

48. Drey M, Henkel M, Petermeise S, Weiss S, Ferrari U, Rottenkolber M, et al. Assessment of Bone and Muscle Measurements by Peripheral Quantitative Computed Tomography in Geriatric Patients. J Clin Densitom. Oct 12 2018. Epub 2018/11/15.

49. Muhlberg A, Museyko O, Laredo JD, Engelke K. A reproducible semi-automatic method to quantify the muscle-lipid distribution in clinical 3D CT images of the thigh. PloS one. 2017;12(4):e0175174. Epub 2017/04/30.

50. Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. Jul 1 2019;48(4):601. Epub 2019/05/14.

51. Oden A, McCloskey EV, Kanis JA, Harvey NC, Johansson H. Burden of high fracture probability worldwide: secular increases 2010-2040. Osteoporos Int. Sep 2015;26(9):2243-8. Epub 2015/05/29.

**Table 1:** Cut points for appendicular lean mass, gait speed and grip strength as incorporated in sarcopenia definitions; and prevalence of sarcopenia according to definition and country cohort. Note EWGSOP2 incorporates definitions of “confirmed” and “severe” sarcopenia.

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Sarcopenia components** | | | | **Prevalence by country cohort** | | |
| **Definition** | **ALM/height2**  **(kg/m2)** | **Gait speed**  **(m/s)** | **Grip strength**  **(kg)** | **Chair stand (s)** | **Hong Kong**  **n=1987** | **Sweden**  **n=2764** | **USA**  **n=5660** |
| Baumgartner | ≤7.26 |  |  |  | 35% | 22% | 21% |
| Delmonico | ≤7.25 |  |  |  | 35% | 21% | 21% |
| FNIH 1 | ALM/BMI<0.789 |  |  |  | 21% | 13% | 17% |
| IWGS | ≤7.23 | <1 |  |  | 18% | 3% | 4% |
| EWGSOP 1 | ≤7.26 | <0.8 | <30 |  | 15% | 2% | 4% |
| EWGSOP2: confirmed | <7.0 |  | <27 | >15 | 10.1% | 2.9% | 5.5% |
| EWGSOP2: severe | <7.0 | ≤0.8 | <27 | >15 | 3.6% | 0.6% | 0.5% |
| SDOC |  | <0.8 | <35.5 |  | 11.2% | 1.0% | 1.7% |
| Morley | ≤6.81 | <1 |  |  | 10% | 2% | 2% |
| AWGS | <7.0 | <0.8 | <26 |  | 10% | 1.3% | 2.0% |
| FNIH 2 | ALM/BMI <0.789 |  | <26 |  | 4% | 0.4% | 0.9% |

**Table 2:** Baseline characteristics and fracture outcomes of study participants by country.

|  |  |  |  |
| --- | --- | --- | --- |
|  | **Hong Kong** | **Sweden** | **USA** |
| Proportion of whole cohort | 99% | 92% | 94% |
| n | 1987 | 2764 | 5660 |
| Person-years | 19592 | 24102 | 61456 |
| Age [mean (range)], years | 72.4 (65-92) | 75.4 (70-81) | 73.5 (64-100) |
| BMI | 23.5±3.1 | 26.3±3.5 | 27.4±3.8 |
| Previous fracture | 14% | 35% | 22% |
| Family history hip fracture | 5% | 13% | 17% |
| Smoker | 12% | 8% | 3% |
| Glucocorticoids | 1% | 2% | 2% |
| Rheumatoid arthritis | 1% | 1% | 5% |
| Excess alcohol | 1% | 2% | 4% |
| BMD FN T-score | -1.4±0.9 | -0.9±1.0 | -0.6±1.1 |
| Gait speed (m/s) | 1.0±0.2 | 1.3±0.3 | 1.2±0.2 |
| Prior falls | 15% | 16% | 20% |
| Grip strength (kg) | 33.9±6.7 | 43.1±7.8 | 41.8±8.4 |
| ALM (kg) | 20.2±2.8 | 24.3±3.2 | 24.3±3.5 |
| Height (cm) | 163±5.7 | 175±6.5 | 174±6.8 |
| ALM/height2 | 7.6±0.9 | 7.9±0.8 | 8.0±0.9 |
|  |  |  |  |
| FRAX MOF without BMD | 6.9±2.9 | 13.5±6.1 | 9.1±4.8 |
| FRAX hip without BMD | 3.4±2.5 | 7.5±5.5 | 3.6±3.9 |
| FRAX MOF with BMD | 6.6±3.2 | 11.4±6.7 | 7.8±4.6 |
| FRAX hip with BMD | 3.0±2.6  (n=1661) | 5.5±6.0  (n=1732) | 2.4±3.4  (n=4138) |
|  |  |  |  |
| FU (hip fx: mean (SD), years | 9.9 (2.8) | 8.7 (2.9) | 10.9 (3.8) |
| Any fx | 11% | 22% | 19% |
| Osteoporotic fx | 9% | 19% | 15% |
| MOF fx | 7% | 16% | 10% |
| Hip fx | 3% | 7% | 4% |

fx=fracture; MOF=Major Osteoporotic Fracture



**Table 3:** Association between sarcopenia definition, and incident fractures. Models are presented adjusted for age and follow-up (FU) time alone and then additionally for either prior falls, FRAX MOF probability without BMD, FRAX MOF probability with BMD or femoral neck BMD T score. Associations with p<0.05 are in bold. N=10,411 except for +FRAX with and without BMD (n=7531). fx=fracture; FN=femoral neck; MOF=Major Osteoporotic Fracture; Ost=Osteoporotic; wo=without

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Exposure (Y/N)** | **Adjustment** | **Any fx** | **Ost fx** | **MOF fx** | **Hip fx** |
| **Baumgartner** | Age, FU time | **1.29 (1.16, 1.42)** | **1.31 (1.17, 1.47)** | **1.39 (1.22, 1.58)** | **1.52 (1.24, 1.85)** |
|  | + prior falls | **1.28 (1.16, 1.42)** | **1.29 (1.16, 1.45)** | **1.38 (1.21, 1.57)** | **1.51 (1.24, 1.84)** |
|  | or + FRAX wo BMD | **1.23 (1.08, 1.39)** | **1.28 (1.11, 1.47)** | **1.38 (1.18, 1.62)** | **1.51 (1.19, 1.92)** |
|  | or + FRAX with BMD | **1.20 (1.06, 1.35)** | **1.25 (1.09, 1.43)** | **1.34 (1.15, 1.57)** | **1.42 (1.12, 1.79)** |
|  | or + FN BMD | 1.04 (0.94, 1.15) | 1.02 (0.91, 1.15) | 1.05 (0.92, 1.20) | 1.01 (0.82, 1.23) |
|  |  |  |  |  |  |
| **Delmonico** | Age, FU time | **1.31 (1.18, 1.45)** | **1.29 (1.13, 1.46)** | **1.40 (1.23, 1.59)** | **1.55 (1.28, 1.89)** |
|  | + prior falls | **1.30 (1.18, 1.44)** | **1.31 (1.17, 1.47)** | **1.39 (1.23, 1.59)** | **1.55 (1.27, 1.89)** |
|  | or + FRAX wo BMD | **1.24 (1.10, 1.41)** | **1.30 (1.13, 1.50)** | **1.40 (1.19, 1.63)** | **1.56 (1.23, 1.97)** |
|  | or + FRAX with BMD | **1.22 (1.08, 1.38)** | **1.27 (1.10, 1.46)** | **1.35 (1.15, 1.58)** | **1.45 (1.15, 1.84)** |
|  | or + FN BMD | 1.06 (0.96, 1.18) | 1.04 (0.93, 1.17) | 1.06 (0.93, 1.22) | 1.03 (0.85, 1.26) |
|  |  |  |  |  |  |
| **FNIH 1** | Age, FU time | 1.04 (0.92, 1.17) | 1.01 (0.88, 1.15) | 1.01 (0.87, 1.19) | 0.81 (0.62, 1.05) |
|  | + prior falls | 1.02 (0.91, 1.15) | 1.00 (0.87, 1.14) | 1.00 (0.86, 1.17) | 0.80 (0.62, 1.04) |
|  | or + FRAX wo BMD | 1.10 (0.94, 1.28) | 1.01 (0.85, 1.20) | 1.00 (0.83, 1.22) | 0.73 (0.53, 1.01) |
|  | or + FRAX with BMD | 1.05 (0.91, 1.21) | 0.96 (0.81, 1.14) | 0.96 (0.79, 1.17) | 0.73 (0.53, 1.00) |
|  | or + FN BMD | 1.06 (0.94, 1.20) | 1.04 (0.90, 1.19) | 1.04 (0.89, 1.21) | 0.84 (0.65, 1.08) |
|  |  |  |  |  |  |
| **FNIH 2** | Age, FU time | 1.13 (0.75, 1.70) | 1.10 (0.70, 1.74) | 1.01 (0.58, 1.76) | 0.87 (0.38, 2.00) |
|  | + prior falls | 1.11 (0.73, 1.67) | 1.09 (0.68, 1.72) | 0.99 (0.57, 1.72) | 0.86 (0.37, 1.98) |
|  | or + FRAX wo BMD | 1.02 (0.61, 1.73) | 1.06 (0.59, 1.88) | 1.07 (0.55, 2.08) | 1.33 (0.48, 3.70) |
|  | or + FRAX with BMD | 1.01 (0.60, 1.69) | 1.05 (0.58, 1.88) | 1.08 (0.55, 2.10) | 1.34 (0.50, 3.93) |
|  | or + FN BMD | 1.06 (0.71, 1.59) | 1.05 (0.66, 1.66) | 0.95 (0.55, 1.64) | 0.85 (0.37, 1.95) |
|  |  |  |  |  |  |
| **IWGS** | Age, FU time | **1.39 (1.15, 1.68)** | **1.41 (1.15, 1.74)** | **1.60 (1.27, 2.01)** | **1.97 (1.42, 2.73)** |
|  | + prior falls | **1.37 (1.14, 1.66)** | **1.41 (1.14, 1.74)** | **1.59 (1.26, 1.99)** | **1.96 (1.42, 2.71)** |
|  | or + FRAX wo BMD | **1.50 (1.20, 1.87)** | **1.54 (1.20, 1.97)** | **1.67 (1.27, 2.19)** | **1.89 (1.28, 2.80)** |
|  | or + FRAX with BMD | **1.46 (1.17, 1.83)** | **1.50 (1.17, 1.92)** | **1.62 (1.23, 2.14)** | **1.87 (1.26, 2.77)** |
|  | or + FN BMD | 1.15 (0.95, 1.39) | 1.13 (0.91, 1.39) | 1.24 (0.98, 1.56) | 1.39 (1.00, 1.93) |
|  |  |  |  |  |  |
| **EWGSOP 1** | Age, FU time | **1.58 (1.29, 1.92)** | **1.72 (1.39, 2.14)** | **1.76 (1.38, 2.26)** | **1.76 (1.21, 2.58)** |
| + prior falls | **1.54 (1.26, 1.88)** | **1.69 (1.36, 2.11)** | **1.73 (1.35, 2.22)** | **1.74 (1.19, 2.55)** |
|  | or + FRAX wo BMD | **1.50 (1.17, 1.92)** | **1.65 (1.26, 2.15)** | **1.65 (1.21, 2.25)** | **1.70 (1.02, 2.80)** |
|  | or + FRAX with BMD | **1.51 (1.18, 1.93)** | **1.66 (1.27, 2.16)** | **1.66 (1.22, 2.25)** | **1.71 (1.04, 2.82)** |
|  | or + FN BMD | **1.29 (1.06, 1.58)** | **1.36 (1.09, 1.69)** | **1.34 (1.04, 1.73)** | **1.18 (0.80, 1.75)** |
|  |  |  |  |  |  |
| **EWGSOP2: confirmed** | Age, FU time | **1.63 (1.35, 1.96)** | **1.73 (1.42, 2.11)** | **1.82 (1.46, 2.27)** | **1.89 (1.37, 2.62)** |
| + prior falls | **1.57 (1.30, 1.90)** | **1.69 (1.38, 2.06)** | **1.76 (1.41, 2.20)** | **1.85 (1.34, 2.56)** |
|  | or + FRAX wo BMD | **1.53 (1.21, 1.93)** | **1.61 (1.25, 2.08)** | **1.65 (1.24, 2.19)** | 1.58 (1.03, 2.42) |
|  | or + FRAX with BMD | **1.50 (1.18, 1.89)** | **1.58 (1.23, 2.03)** | **1.63 (1.22, 2.19)** | **1.55 (1.02, 2.36)** |
|  | or + FN BMD | **1.31 (1.08, 1.58)** | **1.35 (1.10, 1.65)** | **1.39 (1.11, 1.75)** | 1.29 (0.93, 1.80) |
| **EWGSOP2: severe** | Age, FU time | **1.70 (1.12, 2.57)** | **1.92 (1.24, 2.99)** | **2.07 (1.28, 3.33)** | **2.40 (1.26, 4.57)** |
| + prior falls | **1.68 (1.11, 2.56)** | **1.89 (1.22, 2.94)** | **2.01 (1.25, 3.24)** | **2.33 (1.22, 4.44)** |
|  | or + FRAX wo BMD | **2.10 (1.28, 3.41)** | **2.28 (1.35, 3.86)** | **2.21 (1.22, 3.98)** | 1.76 (0.69, 4.47) |
|  | or + FRAX with BMD | **2.25 (1.38, 3.67)** | **2.43 (1.46, 4.16)** | **2.43 (1.35, 4.38)** | 2.14 (0.84, 5.43) |
|  | or + FN BMD | **1.55 (1.02, 2.36)** | **1.71 (1.10, 2.66)** | **1.80 (1.12, 2.91)** | **2.31 (1.21, 4.41)** |
|  |  |  |  |  |  |
| **SDOC** | Age, FU time | **1.57(1.21, 2.03)** | **1.67 (1.26, 2.22)** | **1.51 (1.09, 2.11)** | **2.48 (1.64, 3.76)** |
|  | + prior falls | **1.51 (1.16, 1.96)** | **1.62 (1.22, 2.15)** | **1.46 (1.05, 2.03)** | **2.39 (1.58, 3.63)** |
|  | or + FRAX wo BMD | **1.93 (1.44, 2.58)** | **2.05 (1.49, 2.82**) | **1.76 (1.20, 2.58)** | **2.47 (1.48, 4.15)** |
|  | or + FRAX with BMD | **1.88 (1.41, 2.52)** | **2.01 (1.46, 2.76)** | **1.73 (1.18, 2.53)** | **2.55 (1.53, 4.25)** |
|  | or + FN BMD | **1.52 (1.147, 1.96)** | **1.60 (1.21, 2.12)** | **1.43 (1.03, 1.99)** | **2.36 (1.57, 3.56)** |
|  |  |  |  |  |  |
| **Morley** | Age, FU time | **1.54 (1.19, 1.98)** | **1.52 (1.15, 2.02)** | **1.74 (1.29, 2.36)** | **1.82 (1.16, 2.84)** |
|  | + prior falls | **1.53 (1.19, 1.97)** | **1.51 (1.14, 2.01)** | **1.73 (1.28, 2.33)** | **1.83 (1.17, 2.85)** |
|  | or + FRAX wo BMD | **1.73 (1.29, 2.31)** | **1.65 (1.18, 2.30)** | **1.80 (1.26, 2.59)** | **1.72 (0.99, 2.97** |
|  | or + FRAX with BMD | **1.63 (1.21, 2.19)** | **1.54 (1.10, 2.15)** | **1.68 (1.16, 2.42)** | 1.65 (0.96, 2.85) |
|  | or + FN BMD | 1.20 (0.93, 1.55) | 1.12 (0.84, 1.48) | 1.24 (0.91, 1.69) | 1.18 (0.75, 1.87) |
|  |  |  |  |  |  |
| **AWGS** | Age, FU time | **1.73 (1.36, 2.20)** | **1.83 (1.41, 2.38)** | **1.92 (1.43, 2.57)** | **2.17 (1.41, 3.34)** |
|  | + prior falls | **1.68 (1.31, 2.14)** | **1.78 (1.37, 2.32)** | **1.87 (1.39, 2.51)** | **2.13 (1.38, 3.28)** |
|  | or + FRAX wo BMD | **1.71 (1.27 2.30)** | **1.78 (1.31, 2.41)** | **1.86 (1.29, 2.69)** | **2.04 (1.15, 3.64)** |
|  | or + FRAX with BMD | **1.74 (1.30, 2.35)** | **1.87 (1.35, 2.59)** | **1.93 (1.33, 2.78)** | **2.23 (1.26, 3.95)** |
|  | or + FN BMD | **1.47 (1.15, 1.88)** | **1.52 (1.17, 1.98)** | **1.54 (1.15, 2.07)** | **1.60 (1.03, 2.49)** |

**Table 4:** Hazard ratios for incident major osteoporotic fracture for EWGSOP2 confirmed definition (Y/N) by age band, with p-value for sarcopenia x age interaction.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Age** | **HR (95% CI)** | | | | |
| Adjusted for | Age, FU time | + prior fall | Or + FRAX wo BMD | Or + FRAX with BMD | Or + BMD |
|  |  |  |  |  |  |
| 70 years | **3.24 (1.88, 5.58)** | **3.14 (1.82, 5.43)** | **3.02 (1.54, 5.93)** | **2.37 (1.20, 4.66)** | **2.19 (1.27, 3.78)** |
| 75 years | **2.56 (1.76, 3.74)** | **2.49 (1.71, 3.63)** | **2.41 (1.51, 3.85)** | **2.03 (1.28, 3.23)** | **1.82 (1.24, 2.66)** |
| 80 years | **2.04 (1.59, 2.60)** | **1.98 (1.55, 2.53)** | **1.89 (1.39, 2.58)** | **1.71 (1.26, 2.33)** | **1.71 (1.30, 2.25)** |
| 85 years | **1.73 (1.35, 2.23)** | **1.69 (1.31, 2.17)** | **1.53 (1.11, 2.12)** | **1.49 (1.08, 2.05)** | **1.29 (1.00, 1.67)** |
|  |  |  |  |  |  |
| P-interaction | **0.023** | **0.024** | **0.070** | 0.22 | **0.049** |

**Figure 1:** Associations between sarcopenia definitions (IWGS, EWGSOP2 “confirmed”, AWGS and SDOC) and risk of incident major osteoporotic fracture. Data shown are the point estimate for the hazard ratio (sarcopenia yes/no) and 95% CI. Models are presented adjusted for age and follow-up time alone and then additionally for either prior falls, FRAX MOF probability without BMD, FRAX MOF probability with BMD or femoral neck BMD T-score.